Dimerix Says Phase 3 Clinical Trial Data Review Shows Over 90% Statistical Power to Detect Proteinuria Treatment Effect; Shares Reach Two-Year Low

-- Dimerix (ASX:DXB) said an external statistical blinded review of the data from the ACTION3 phase 3 clinical trial, evaluating its DMX-200 drug candidate in patients with focal segmental glomerulosclerosis, confirmed that the study had an over 90% statistical power to detect the treatment effect for the proteinuria primary endpoint, according to a Tuesday Australian bourse filing.

The US Food and Drug Administration (FDA) previously confirmed that the proposed primary endpoint of percent reduction in proteinuria compared to placebo could support traditional approval of its DMX-200 drug candidate via the 505(b)(1) pathway, should the findings of the study be positive.

Its shares fell 35% in recent trading on Tuesday, reaching a two-year low.

Torque Metals公司称，钻探结果持续显示西澳大利亚金矿项目矿化范围扩大；股价下跌5%。

根据周二提交给澳大利亚证券交易所的文件，Torque Metals（ASX：TOR）在收到钻探结果后，于3月份季度继续扩大其位于西澳大利亚的Paris金矿床的矿化范围，其中包括在222米深处发现20米厚、金品位为5.79克/吨的矿段。该公司表示，计划进行更多金刚石钻探，以更好地确定该矿床新的高品位矿脉边界，并计划在第二季度更新Paris项目的矿产资源量中期估算。 Torque Metals在3月份季度末的现金余额约为1220万澳元，该公司表示，这使其拥有“雄厚的资本实力”，可以支持正在进行的多钻机钻探作业。该公司股价在周二的交易中下跌了5%。

$ASX:TOR

哲尚证券第一季度利润增长35%，营收增长41%；股价上涨4%。

据周二在上海证券交易所发布的公告显示，浙商证券（SHA:601878）第一季度归属于股东的净利润同比增长35%，从上年同期的5.556亿元人民币增至7.512亿元人民币。每股收益同比增长42%，从上年同期的0.12元人民币增至0.17元人民币。营业收入同比增长41%，从上年同期的16.8亿元人民币增至23.6亿元人民币。周二午后交易时段，浙商证券股价上涨4%。

$SHA:601878

Dimerix Says Phase 3 Clinical Trial Data Review Shows Over 90% Statistical Power to Detect Proteinuria Treatment Effect; Shares Reach Two-Year Low

相关文章

Torque Metals公司称，钻探结果持续显示西澳大利亚金矿项目矿化范围扩大；股价下跌5%。

杰富瑞将印度煤炭公司（Coal India）的目标股价从485印度卢比上调至500印度卢比，维持“买入”评级。

哲尚证券第一季度利润增长35%，营收增长41%；股价上涨4%。